Cargando…
Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is characterized by the spontaneous development of wheals, itching, and/or angioedema, for ≥6 weeks. In China, non‐sedating H1‐antihistamines (H1AH) are the recommended first‐line treatment, with escalation up to 4× the standard dose in symptomatic patients to ach...
Autores principales: | Yuan, Weiru, Hu, Shuling, Li, Min, Yang, Lijia, Liu, Lingling, Zheng, Min, Guo, Zaipei, Song, Zhiqiang, Zhang, Chunlei, Diao, Qingchun, Xu, Jinhua, Richard, Alexia, Patwardhan, Moreshwar, Lyu, Tianmeng, Uddin, Alkaz, Fogel, Robert, Ligueros‐Saylan, Monica, Zheng, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286033/ https://www.ncbi.nlm.nih.gov/pubmed/34984792 http://dx.doi.org/10.1111/dth.15303 |
Ejemplares similares
-
Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
por: Su, Nan, et al.
Publicado: (2023) -
Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016) -
Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018) -
Expert consensus on the use of omalizumab in chronic urticaria in China()
por: Zhao, Zuotao, et al.
Publicado: (2021) -
Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
por: Nam, Young-Hee, et al.
Publicado: (2012)